Presenting features
| Characteristic . | Randomized treatment, no. (%) . | P* . | ||
|---|---|---|---|---|
| Total . | MP . | TG . | ||
| Age, y | .49 | |||
| 1 to 1.99 | 165 (8.1) | 79 (7.8) | 86 (8.5) | |
| 2 to 5.99 | 1402 (69.2) | 711 (70.4) | 691 (67.9) | |
| 6 to 9.99 | 460 (22.7) | 220 (21.8) | 240 (23.6) | |
| Sex | .37 | |||
| Boys | 1129 (55.7) | 552 (54.7) | 577 (56.7) | |
| Girls | 898 (44.3) | 458 (45.3) | 440 (43.3) | |
| Race/ethnicity† | .27 | |||
| White | 1376 (68.2) | 677 (67.2) | 699 (69.1) | |
| Black | 72 (3.6) | 35 (3.5) | 37 (3.7) | |
| Hispanic | 444 (22.0) | 221 (22.0) | 223 (22.1) | |
| Other | 125 (6.2) | 73 (7.3) | 52 (5.1) | |
| Down syndrome | .98 | |||
| Yes | 57 (2.8) | 28 (2.8) | 29 (2.9) | |
| CNS status† | .16 | |||
| CNS-1 | 1831 (92.8) | 902 (91.7) | 929 (93.8) | |
| CNS-2 | 113 (5.7) | 66 (6.7) | 47 (4.8) | .07¶ |
| CNS-3 | 30 (1.5) | 16 (1.6) | 14 (1.4) | |
| WBC, ×109/L | .52 | |||
| Lower than 20 | 1660 (81.9) | 821 (81.3) | 839 (82.5) | |
| 20 or higher | 367 (18.1) | 189 (18.7) | 178 (17.5) | |
| Hepatomegaly | .01 | |||
| Yes | 999 (49.6) | 466 (46.4) | 533 (52.8) | |
| Immunophenotype† | .60 | |||
| B lineage | 1802 (93.3) | 681 (94.1) | 689 (93.5) | |
| T lineage | 130 (6.7) | 43 (5.9) | 48 (6.5) | |
| Trisomies 4, 10, and 17‡ | .96 | |||
| Yes | 121 (13.7) | 60 (13.9) | 61 (13.6) | |
| ETV6-RUNX1§ | .93 | |||
| Yes | 225 (23.9) | 115 (24.2) | 110 (23.7) | |
| Day-14 marrow status† | .86 | |||
| M1‖ | 1795 (91.1) | 890 (90.9) | 905 (91.2) | |
| M2 | 176 (8.9) | 89 (9.1) | 87 (8.8) | |
| Characteristic . | Randomized treatment, no. (%) . | P* . | ||
|---|---|---|---|---|
| Total . | MP . | TG . | ||
| Age, y | .49 | |||
| 1 to 1.99 | 165 (8.1) | 79 (7.8) | 86 (8.5) | |
| 2 to 5.99 | 1402 (69.2) | 711 (70.4) | 691 (67.9) | |
| 6 to 9.99 | 460 (22.7) | 220 (21.8) | 240 (23.6) | |
| Sex | .37 | |||
| Boys | 1129 (55.7) | 552 (54.7) | 577 (56.7) | |
| Girls | 898 (44.3) | 458 (45.3) | 440 (43.3) | |
| Race/ethnicity† | .27 | |||
| White | 1376 (68.2) | 677 (67.2) | 699 (69.1) | |
| Black | 72 (3.6) | 35 (3.5) | 37 (3.7) | |
| Hispanic | 444 (22.0) | 221 (22.0) | 223 (22.1) | |
| Other | 125 (6.2) | 73 (7.3) | 52 (5.1) | |
| Down syndrome | .98 | |||
| Yes | 57 (2.8) | 28 (2.8) | 29 (2.9) | |
| CNS status† | .16 | |||
| CNS-1 | 1831 (92.8) | 902 (91.7) | 929 (93.8) | |
| CNS-2 | 113 (5.7) | 66 (6.7) | 47 (4.8) | .07¶ |
| CNS-3 | 30 (1.5) | 16 (1.6) | 14 (1.4) | |
| WBC, ×109/L | .52 | |||
| Lower than 20 | 1660 (81.9) | 821 (81.3) | 839 (82.5) | |
| 20 or higher | 367 (18.1) | 189 (18.7) | 178 (17.5) | |
| Hepatomegaly | .01 | |||
| Yes | 999 (49.6) | 466 (46.4) | 533 (52.8) | |
| Immunophenotype† | .60 | |||
| B lineage | 1802 (93.3) | 681 (94.1) | 689 (93.5) | |
| T lineage | 130 (6.7) | 43 (5.9) | 48 (6.5) | |
| Trisomies 4, 10, and 17‡ | .96 | |||
| Yes | 121 (13.7) | 60 (13.9) | 61 (13.6) | |
| ETV6-RUNX1§ | .93 | |||
| Yes | 225 (23.9) | 115 (24.2) | 110 (23.7) | |
| Day-14 marrow status† | .86 | |||
| M1‖ | 1795 (91.1) | 890 (90.9) | 905 (91.2) | |
| M2 | 176 (8.9) | 89 (9.1) | 87 (8.8) | |
χ2, 2-sided P value; P values reflect the comparison between TG and MP cohorts with respect to the categories within each characteristic.
Fewer than 2027 cases reflect missing data.
Among 882 cases with centrally approved cytogenetics.
Among 940 cases analyzed by reverse-transcriptase–polymerase chain reaction for ETV6-RUNX1.
Includes patients with M1 marrow on day 7.
P value reflects CNS-2 vs CNS-1.